A study in a murine model using an E7 peptide-based vaccine in combination with PADRE and a Toll-like receptor 3 (TLR3) agonist indicated better CTL responses and anti-tumor protection than the vaccine without the T helper epitope [35]. This evidence concerns the gene TLR3 and neoplasm.